REZUROCK™ (belumosudil) Once-Daily Dosing for Your Patients

Dosing

happy young men and women gathered around a table while eating food

A once-daily oral tablet for patients with cGVHD¹

Each pale-yellow oblong 200-mg tablet is debossed with “KDM” on one side and “200” on the other side.¹

Not actual size.

The recommended dose of REZUROCK is 200 mg once daily administered orally

Advise patients to take REZUROCK at approximately the same time each day with a meal
If the patient misses a dose of REZUROCK, instruct the patient not to take extra doses to make up for the missed dose
Inform patients that the REZUROCK tablet should be swallowed whole with a glass of water without cutting, crushing or chewing the tablet

Dose modifications for adverse reactions are related to the
grade of cGVHD severity¹

Recommended dose modifications for REZUROCK for adverse reactions

table of dose modifications for REZUROCK, including hepatotoxicity and other adverse reactions

Monitor total bilirubin, AST and ALT at least monthly

Please see the full Prescribing Information for additional guidance for other populations

Dose modifications for patients with renal or hepatic impairment¹

Renal impairment

Patients with mild to moderate renal impairment

No clinically significant differences in REZUROCK pharmacokinetics observed

Patients with severe renal impairment

No data are available for patients with severe renal impairment

Hepatic impairment

Patients with hepatic impairment

No data are available for patients with hepatic impairment

Use in specific populations¹

Pregnancy

REZUROCK can cause fetal harm when administered to pregnant women
Advise pregnant women of the potential risk to the fetus. Advise women of reproductive potential, and their male partners, to use effective contraception during treatment with REZUROCK and for at least 1 week after the last dose
of REZUROCK

Pediatric use

The safety and effectiveness of REZUROCK in pediatric patients aged <12 years have not been established

Geriatric use

Of the 186 patients with cGVHD in clinical studies of REZUROCK, 26% were aged ≥65 years. No clinically meaningful differences in safety or effectiveness of REZUROCK were observed in comparison to younger patients

Drug interactions¹

Strong CYP3A Inducers: Increase the dosage of REZUROCK to 200 mg twice daily when coadministered with strong CYP3A inducers
Proton Pump Inhibitors: Increase the dosage of REZUROCK to 200 mg twice daily when coadministered with proton pump inhibitors

Please see the full Prescribing Information for additional information on drug interactions.

Storage¹

Store REZUROCK at room temperature, ranging from 68 °F to 77 °F (20 °C-25 °C); excursions are permitted from 59 °F to 86 °F (15 °C-30 °C).

Dispense REZUROCK to patients in its original container only. Store REZUROCK in its original container to protect from moisture. Replace the cap securely each time after opening. Do not discard desiccant.

Help your patients get started on REZUROCK.

LEARN ABOUT KADMON ASSIST^TM